Riese, Christoph G. U. ; Seitz, Stephan ; Schipper, Meike L. ; Behr, Thomas M.
Alternative Links zum Volltext:DOIVerlag
| Dokumentenart: | Artikel |
|---|
| Titel eines Journals oder einer Zeitschrift: | European Journal of Nuclear Medicine and Molecular Imaging |
|---|
| Verlag: | SPRINGER |
|---|
| Ort der Veröffentlichung: | NEW YORK |
|---|
| Band: | 36 |
|---|
| Nummer des Zeitschriftenheftes oder des Kapitels: | 11 |
|---|
| Seitenbereich: | S. 1767-1773 |
|---|
| Datum: | 2009 |
|---|
| Institutionen: | Medizin > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) |
|---|
| Identifikationsnummer: | | Wert | Typ |
|---|
| 10.1007/s00259-009-1153-6 | DOI |
|
|---|
| Stichwörter / Keywords: | CANCER CELL-LINES; SODIUM/IODIDE-SYMPORTER; NA+/I-SYMPORTER; IN-VIVO; SALIVARY-GLAND; BREAST-CANCER; TC-99M PERTECHNETATE; PROSTATE-CANCER; GASTRIC-MUCOSA; MAMMARY-GLAND; Sodium iodide symporter; Re-186-Perrhenate; Rhenium-186; Neuroendocrine tumours; Radionuclide therapy |
|---|
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin |
|---|
| Status: | Veröffentlicht |
|---|
| Begutachtet: | Ja, diese Version wurde begutachtet |
|---|
| An der Universität Regensburg entstanden: | Ja |
|---|
| Dokumenten-ID: | 66794 |
|---|
Web of Science
Zusammenfassung
ReO (4) (-) has similar kinetics regarding the sodium iodide symporter (NIS) to I- and TcO (4) (-) in NIS-expressing tissue. We investigated the therapeutic potential of (ReO)-Re-186 (4) (-) in NIS-transfected neuroendocrine tumour tissue. For experiments, the stably NIS-transfected pancreatic neuroendocrine cancer cell line Bon1C was used. NIS-mediated internalization and externalization ...
Zusammenfassung
ReO (4) (-) has similar kinetics regarding the sodium iodide symporter (NIS) to I- and TcO (4) (-) in NIS-expressing tissue. We investigated the therapeutic potential of (ReO)-Re-186 (4) (-) in NIS-transfected neuroendocrine tumour tissue. For experiments, the stably NIS-transfected pancreatic neuroendocrine cancer cell line Bon1C was used. NIS-mediated internalization and externalization experiments in vitro and a biodistribution study in nude mice bearing Bon1C xenografts were performed. A therapy study was also conducted consecutively in nude mice xenografted with Bon1C in which the mice were injected intravenously with (NaReO4)-Re-186. In vitro studies showed exponential internalization and efflux kinetics of (ReO)-Re-186 (4) (-) in the cell line. The biodistribution study showed high uptake of (ReO)-Re-186 (4) (-) in NIS-expressing tumours. Tumour growth inhibition was significant after injection of (ReO4)-Re-186 in two groups of animals treated with activity levels below the determined maximum tolerable activity as compared to controls. These results indicate that the use of (ReO)-Re-186 (4) (-) in the treatment of NIS-expressing neuroendocrine tumours is feasible and support the concept of using NIS as a therapeutic target for (ReO)-Re-186 (4) (-) .
Altmetric